Geneva, Switzerland

Cristiano Migliorini

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Genentech, Inc.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cristiano Migliorini. Retrieved from https://idiyas.com/inventor/cristiano-migliorini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cristiano Migliorini: Innovator in Diabetes Treatment

Introduction

Cristiano Migliorini is an inventor based in Genf, Switzerland. He is focused on developing innovative solutions for health-related issues, particularly in the field of diabetes treatment. Although he currently holds no granted patents, his work is significant in the realm of pharmaceutical advancements.

Latest Patent Applications

Cristiano Migliorini's latest patent applications include the "Use of Aminodihydrothiazines for the Treatment or Prevention of Diabetes." This invention relates to compounds of formula I, wherein Rto Rare as defined herein, as well as pharmaceutically acceptable salts thereof. The pharmaceutical compositions containing such compounds and methods for using them aim to treat or prevent diabetes, particularly type 2 diabetes. This application highlights his commitment to addressing critical health challenges through innovative compounds.

Conclusion

Cristiano Migliorini is an emerging inventor whose work in diabetes treatment showcases his dedication to improving health outcomes. His latest patent applications reflect a promising direction in pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…